SynthesisBMC infectious diseases2026
The global detection rate of human papillomavirus DNA in ovarian cancer: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Natural compounds targeting glycolysis and TME in ovarian cancer: from metabolic crosstalk to therapeutic potential.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer remains the most lethal gynecological malignancy, with high mortality rates despite advancements in treatment. Microbial infections play a significant role in inducing carcinogenesis. This study aimed to investigate the prevalence of human papillomavirus (HPV) in ovarian cancer cases worldwide.
methodsFollowing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive systematic search was conducted in PubMed, Web of Science, and Embase databases from 2000 to 2024 using relevant keywords. Data were statistically analyzed using Stata software.
resultsAfter screening and data extraction, 25 original articles were included in the final analysis. The pooled estimate of HPV infection among ovarian cancer patients was 22.9% (95% CI, 15.8–32.1). Subgroup analyses showed the highest prevalence in studies from Asia (26.6%; 95% CI, 18.8–36.4) and Europe (20.9%; 95% CI, 7.2–47.3). HPV types 16 and 18 were the most frequent genotypes detected worldwide (40.2% and 25.9%, respectively). When stratified by diagnostic methods, PCR-based methods (including conventional, real-time, and nested PCR) showed a pooled HPV estimate of 18.9% (95% CI, 12.6–27.3), whereas in situ hybridization (ISH)-based studies reported a substantially higher estimate of 48.9% (95% CI, 34.9–63.1).
conclusionThis meta-analysis indicates that HPV DNA may be detected in a proportion of ovarian cancer cases, with higher prevalence reported in some Asian populations. However, substantial heterogeneity and conflicting evidence, including studies reporting no HPV detection, warrant cautious interpretation. The predominance of HPV-16, HPV-18, and HPV-33 in certain populations requires further investigation. Future well-designed studies, especially in under-represented regions, are needed to clarify the epidemiological patterns and detection trends of HPV in ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.